Adial Pharmaceuticals logo
Adial Pharmaceuticals ADIL
$ 1.75 0.87%

Annual report 2025
added 03-05-2026

report update icon

Adial Pharmaceuticals Net Debt 2011-2026 | ADIL

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt Adial Pharmaceuticals

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - - -5.85 M -4.4 M -6.78 M -3.87 M 671 K 146 K -162 K - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
671 K -6.78 M -2.89 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
163 M - 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
-60.6 M - 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
-65.1 M - 5.93 % $ 314 M canadaCanada
Akero Therapeutics Akero Therapeutics
AKRO
-340 M - - $ 3.67 B usaUSA
Akouos Akouos
AKUS
-92.9 M - 0.23 % $ 488 M usaUSA
I-Mab I-Mab
IMAB
-1.06 B - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
-402 M - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
2.27 M - 2.54 % $ 160 B franceFrance
Albireo Pharma Albireo Pharma
ALBO
-239 M - -0.23 % $ 916 M usaUSA
Biophytis SA Biophytis SA
BPTS
-4.01 M - -13.47 % $ 169 M franceFrance
REGENXBIO REGENXBIO
RGNX
39 M $ 8.39 -0.83 % $ 433 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
-3.44 M - 10.36 % $ 9.8 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-6.17 M - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-824 K - -1.52 % $ 24.7 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
-76.6 M $ 2.79 0.18 % $ 280 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-36 M - - $ 26.5 M usaUSA
Rigel Pharmaceuticals Rigel Pharmaceuticals
RIGL
12.5 M $ 26.27 -0.08 % $ 473 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
12.6 M - -10.17 % $ 12.2 K usaUSA
Aptinyx Aptinyx
APTX
-33.8 M - -39.0 % $ 4.57 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
114 M - -24.86 % $ 820 K usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
-165 M $ 2.88 4.35 % $ 599 M usaUSA
Acasti Pharma Acasti Pharma
ACST
-27.4 M - 4.01 % $ 150 M canadaCanada
Equillium Equillium
EQ
-29.6 M $ 2.08 0.97 % $ 119 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
246 M - - - russiaRussia
Adverum Biotechnologies Adverum Biotechnologies
ADVM
31.1 M - - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
-2.08 M - 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
3.42 M - -9.65 % $ 45.9 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
-657 K - - $ 7.46 M israelIsrael
Avenue Therapeutics Avenue Therapeutics
ATXI
-3.13 K - -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-187 M $ 1.33 -0.38 % $ 339 M britainBritain
Atreca Atreca
BCEL
33.1 M - -11.76 % $ 5.79 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
-3.56 B - 0.49 % $ 251 B cayman-islandsCayman-islands
Relay Therapeutics Relay Therapeutics
RLAY
-75.8 M $ 9.87 2.81 % $ 1.41 B usaUSA
bluebird bio bluebird bio
BLUE
-163 M - - $ 546 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
-33.1 M - -4.8 % $ 255 M usaUSA
Cara Therapeutics Cara Therapeutics
CARA
-9.78 M - -3.03 % $ 260 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
-42.5 M - - $ 3.74 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-30.2 M - - $ 1.01 B usaUSA
Avid Bioservices Avid Bioservices
CDMO
17.5 M - - $ 789 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
-783 M - - $ 867 M germanyGermany
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
-23.8 M - -74.18 % $ 955 K usaUSA
Avidity Biosciences Avidity Biosciences
RNA
-333 M $ 13.12 0.23 % $ 1.81 B usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
-141 M $ 48.11 2.17 % $ 4.33 B schweizSchweiz
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
-107 M $ 4.54 0.11 % $ 870 M canadaCanada
Lixte Biotechnology Holdings Lixte Biotechnology Holdings
LIXT
-5.07 M $ 2.95 -1.34 % $ 5.65 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
-1.04 M - 1.93 % $ 17.4 M usaUSA
Royalty Pharma plc Royalty Pharma plc
RPRX
5.41 B $ 47.33 0.64 % $ 20.3 B usaUSA
Kazia Therapeutics Limited Kazia Therapeutics Limited
KZIA
-5.43 M $ 6.96 -4.66 % $ 922 M australiaAustralia
Allakos Allakos
ALLK
-25 M - - $ 28.6 M usaUSA
Brickell Biotech Brickell Biotech
BBI
-29.7 M - -5.38 % $ 6.06 M usaUSA